sars-cov, in vero cells

SARS-CoV-IN-1 is an effective SARS-CoV replication inhibitor(EC50 of 4.9 μM in Vero cells).

SARS-CoV-IN-2 is an effective SARS-CoV replication inhibitor

SARS-CoV-IN-3 is an effective SARS-CoV replication inhibitor.

SARS-CoV-2 Mpro-IN-9 (SARS-CoV-2 Mpro IN 9) 是一种高效的 SARS-CoV-2 Mpro 抑制剂，IC50 值为 80 nM。SARS-CoV-2 Mpro-IN-9 具有抗病毒活性，抑制3C样半胱氨酸蛋白酶，可用于研究病毒感染。

EIDD-1931 (Beta-d-N4-hydroxycytidine) 是一种核苷类抗病毒试剂 ，可抑制丙型肝炎病毒、基孔肯亚病毒和委内瑞拉马脑炎病毒的复制活性。

SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) 作为SARS-CoV-2 3CLpro的变构抑制剂，具有0.43 μM的IC50值。在与Vero-E6细胞共孵育时，此化合物还展示了出色的细胞通透性，能有效穿透细胞膜。

SARS-CoV-2 Mpro-IN-34 (Compound 26) 作为SARS-CoV-2 Mpro的有效抑制剂，其IC50值为6 nM。该化合物同样抑制OC43 Mpro，IC50为33 nM。在SARS-CoV-2感染的Vero E6细胞中，SARS-CoV-2 Mpro-IN-34展现出了明显的抗病毒活性，其EC50值为0.103 μM。

SARS-CoV-2 Mpro-IN-29 (Compound 7) 是一种可抑制 SARS-CoV-2 主蛋白酶 (Mpro) 的化合物，其对 Mpro 的 IC50 为 310 nM，在 Vero 细胞中的 EC50 为 0.5 μM。通过结合 Mpro 活性位点，SARS-CoV-2 Mpro-IN-29 阻止病毒多聚蛋白的切割，展现出显著的抗病毒活性，并具有代谢增强功能。这一化合物有望应用于 SARS-CoV-2 抗病毒药物的研究。

CKP-25 是一种能够抑制Spike RBD-ACE2相互作用的化合物，可阻止病毒入侵宿主细胞，进而减少病毒的复制与感染。CKP-25 对SARS-CoV-2表现出抑制效果，其在 Vero E6 细胞中的IC50为 3.5 μM。

SARS-CoV-2 PLpro-IN-1 (Compound 85) 是一种非共价竞争性抑制剂，针对 SARS-CoV-2 PLpro 的 IC50 为 15.06 μM，Ki 为 22.93 μM。此外，SARS-CoV-2 PLpro-IN-1 在 Vero 细胞中抑制细胞增殖的 IC50 为 7.47 μM。

Peptide originally derived from SARS-CoV Spike (S) protein; corresponds to amino acid residues 668 to 679. Highly potent inhibitor of SARS-CoV S protein and ACE2 interaction (IC50 = 1.88 nM in biochemical assay). Inhibits interaction of SARS-CoV S protein and Vero E6 cells in vitro. Please note, this peptide displays 80% sequence identity to homologous site on SARS-CoV-2 S-protein (residues 689-697).

MProinhibitor 11b is an inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (MPro; IC50= 0.04 μM in a TR-FRET assay).1It reduces viral yield in the culture supernatant of SARS-CoV-2-infected Vero E6 cells (EC50= 0.72 μM). MProinhibitor 11b also reduces viral RNA copy numbers in the same model when used at concentrations ranging from 1.85 to 50 μM. 1.Dai, W., Zhang, B., Jiang, X.-M., et al.Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main proteaseScience368(6497)1331-1335(2020)

Ribavirin-13C5is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin is an antiviral guanosine nucleoside analog.1,2Upon entry into cells, ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg) reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV), hepatitis C virus (HCV), and viral hemorrhagic fevers. 1.Gilbert, B.E., and Knight, V.Biochemistry and clinical applications of ribavirinAntimicrob. Agents Chemother.30(2)201-205(1986) 2.Gordon, C.J., Tchesnokov, E.P., Woolner, E., et al.Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potencyJ. Biol. Chem.295(20)6785-6797(2020) 3.Kirsi, J.J., North, J.A., McKernan, P.A., et al.Broad-spectrum antiviral activity of 2-β-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agentAntimicrob. Agents Chemother.24(3)353-361(1983) 4.Wang, M., Cao, R., Zhang, L., et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30(3)269-271(2020) 5.Wilson, S.Z., Knight, V., Wyde, P.R., et al.Amantadine and ribavirin aerosol treatment of influenza A and B infection in miceAntimicrob. Agents Chemother.17(4)642-648(1980)

SARS-CoV-2-IN-7 demonstrates potent inhibition of viral replication in SARS-CoV-2-infected Vero E6 cells with an IC50 value of 844 nM.

SARS-CoV-2-IN-36 是一种针对SARS-CoV-2 Mpro(SARS-CoV)的有效抑制剂, 其酶测定的IC50值为2.37 μM，Kd值为1.19 μM。在Vero细胞试验中, SARS-CoV-2-IN-36 对UC-1074、RG2674 及NVDBB-2220 SARS-CoV-2变体展现了抗病毒活性。

SARS-CoV-2-IN-54（Compound 2）为针对SARS-CoV-2的抑制剂，展现出抗病毒活性。它能在Vero E6细胞中抑制SARS-CoV-2，其IC50值为21.4 μM。

SARS-CoV-2-IN-56（Compound 63）是具有抗病毒活性的SARS-CoV-2抑制剂，能在Vero E6 细胞中抑制SARS-CoV-2，其IC50为0.7 μM。

SARS-CoV-2 3CLpro-IN-14（compound 11j）为口服活性SARS-CoV-2 3CLpro抑制剂，于Vero E6细胞中对SARS-CoV-2展现出高效抗活性（EC50=0.18 μM），且具备低细胞毒性（CC50>50 μM）。

SARS-CoV-2 3CLpro-IN-18（Compound 3C）为一种共价SARS-CoV-2 3CLpro抑制剂，具有0.478 μM的IC50值。在Vero E6细胞中对SARS-CoV-2展现出2.499 μM的EC50抑制活性，并显示出较低的细胞毒性（CC50> 200 μM）。

SARS-CoV-2-IN-63（Compound R3e）是一种针对SARS-CoV-2病毒复制的抑制剂，具备较低的细胞毒性。在Vero E6细胞和Calu-3细胞中对SARS-CoV-2的抑制作用表现出EC50值分别为1.99 μM与1.92 μM。

SARS-CoV-2-IN-62 (Compound R3b) 为SARS-CoV-2复制抑制剂，细胞毒性较低。在Vero E6细胞和Calu-3细胞中，其抑制病毒复制的EC50值分别为2.97 μM与3.82 μM。

P315V3 是一种冠状病毒 (coronavirus) 广谱抑制剂，能够有效抑制 SARS-CoV-2 的原型 PT、Delta、BA.1 和 BA.4 毒株，其 IC50 分别为 10.9、8.9、8.6 和 2.7 nM。在 Vero 细胞中，P315V3 显示细胞毒性，CC50 为 4.3 μM。此外，在小鼠模型中，P315V3 展现出明显的抗感染活性。